FACSIMILE COVER SHEET

FEB 2 7 2004

Licata & Tyrrell P.C.

66 E. Main Street Marlton, New Jersey OFFICIAL

Tel: (856) 810-1515 Fax: (856) 810-1454

E-Mail: JMLicata@licataandtyrrell.com

February 27, 2004

GROUP: 1635

FAX NUMBER: 1-703-872-9306

ATTORNEY DOCKET NO.: ISPH-0625

SERIAL NO.: 10/057,550

FILED: January 25, 2002

NUMBER OF PAGES: 11 (including this sheet)

MESSAGE: Attached is a General Transmittal Letter (in duplicate); four Terminal Disclaimers and Authorization to charge deposit account \$440.00 for Terminal Disclaimer fees (\$110.00 for each Terminal Disclaimer).

URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

CONFIDENTIALITY NOTICE

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ics) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying distribution or taking of any action in reliance on the coments of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the recur of the materials. Thank you.

	TRANSMITTAL LETTER (General - Patent Pending)		Docket No. TSPH-0625		
In Re Application Of: B	In Re Application Of: Brett P. Monia				
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635		
Title: ANTISENSE OL	IGONUCLEOTIDE MODULATI	ON BY RAF GENE EXPRES	SION		
,	TO THE COMMISSI	ONER FOR PATENTS:	· · · · · · · · · · · · · · · · · · ·		
Transmitted herewith is: Four Terminal Disclain	nèrs				
as described belo ⊠ Charge th ⊠ Credit an;	is required. nount of is atta greby authorized to charge and co	* * ***	50-1619		
Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454	ignature	on first class mall und Commissioner for 22313-1450. Signature	s document and fee is being deposited with the U.S. Postal Service as der 37 C.F.R. 1.8 and is addressed to the Patents, P.O. Box 1450, Alexandria, VA of Person Mailing Correspondence		

		<u> AECEIVED</u>	
	TRANSMITTAL LETTER (General - Patent Pending)	CENTRAL FAX CENTER FEB 2 7 2004	Docket No. ISPE-0625
In Re Application Of: 331	rett P. Monia	OFFI	CIAL
Serial No.	Filing Date	Examiner	Group Art Unit
10/057,550	January 25, 2002	James Schultz	1635
Title: ANTISENSE OLI	GONUCLEOTIDE MODULATI	ON BY RAF GENE EXPRESSION	Ÿ
	· 		· · · · · · · · · · · · · · · · · · ·
	TO THE COMMISSION	ONER FOR PATENTS:	
Transmitted herewith is:			
Four Terminal Disclaim	ers		
•			
,	•		
in the above identified app	plication.		
☐ No additional fee is	required.	•	
A check in the amo			
The Director is here as described below	eby authorized to charge and cre	edit Deposit Account No.	50-1619
	overpayment.		•
Charge any	additional fee required.		
	•		
January 11 (132)		Dated: February 27, 2004	
•	Jature		
Jane Massey Licata Reg. No. 32,257			
Licata & Tyrrell P.C. 66 E. Main Street		I certify that this docu	ment and fee is being deposited
Mariton, NJ 08053		on first class mail under 37 (with the U.S. Postal Service as C.F.R. 1.8 and is addressed to the
Tel: 856-810-1515 Fax: 856-810-1454			s, P.O. Box 1450, Alexandria, VA
LCLI-ATO-ACA		EZ313*1430.	
		Simulatura of Dom.	on Mailing Correspondence
		Signusure of Ferse	ле заминев Солтегропивнов
o:		J	
·		Typed or Printed Name of	f Person Mailing Correspondence

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) Applicant(s): Brett P. Monis Serial No. Filing Date Examiner Group Art Unit 1635 Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION I hereby certify that this Terminal Disclaimer I thereby certify that this Terminal Disclaimer I thereby of convergence of convergence and or is being faced in the United States Patent and Trademark Office (Fax. No. 763-872-9306.) on February 27, 2004 (Date) Jane Massey Licats (Dynd or Placed Fame of Person Signing Certificate) Value of the Conference of the Malling.					Docket No.
Serial No. 10/057,550 Serial No. January 25, 2002 Serial No. January 25, 2002 Sames Schultz Group Art Unit 1635 Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION I hereby certify that this Terminal Disclaimer (Heavilty type of correspondence) (Heavilty type of Correspondence) The private of Privated Name of Prenon Signing Certificates (Types or Privated Name of Prenon Signing Certificates) (Signature) Note: Each paper must have its own certificate of mailing.	CERTIFICATE OF T	RANSMISSION BY FAC	SIMILE (37 CFR 1.8)		
Serial No. 10/057,550 January 25, 2002 James Schultz Group Art Unit 1635 Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION I hereby certify that this Terminal Disclaimer (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Princed Name of Ferron Signing Certificate) (Signature) Note: Each paper must have its own certificate of spating.	Applicant(s): Brett P. Moi	nîa		L	ISPH-0625
Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION Thereby certify that this Terminal Disclaimer (Identify tops of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					Group Art Unit
Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION Thereby certify that this Terminal Disclaimer (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on February 27, 2004 (Date) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.	Şerial No.	=			· ·
Terminal Disclaimer (Identify tops of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306.) On February 27, 2004 (Date) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) Valor State (Signature) Note: Each paper must have its own certificate of mailing.	10/057,550	January 25, 2002	James Schultz		1033
Terminal Disclaimer (Identify tops of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306.) On February 27, 2004 (Date) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) Valor State (Signature) Note: Each paper must have its own certificate of mailing.		OVECODE CONTROL MODIL	ATTON BY PAR GRNE EXI	PRESSI	ION
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.	Invention: ANTISENSE	OLIGOROCLEOTIBE MODE	DATION DI ROL GENE EN		
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306.) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306.) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Identify type of correspondence) is being facsimile transmitted to the United States Patent and Tradernark Office (Fax. No. 703-872-9306.) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on February 27, 2004 (Data) Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.	I hereby certify that this				
Jane Massey Licata	, , , , , , , , , , , , , , , , , , ,	und to the Lighted Chates Dates		No 7	03-872-9306)
Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) Scale On Stocked (Signature) Note: Each paper must have its own certificate of mailing.	is being facsimile transmit	tied to the United States Paten	ranu mademan, Ombe (rax.	<u>/</u>	
Jane Massey Licata (Typed or Printed Name of Person Signing Certificate) Scale On Stocked (Signature) Note: Each paper must have its own certificate of mailing.	on February 27	, 2004			
(Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.					
(Typed or Printed Name of Person Signing Certificate) (Signature) Note: Each paper must have its own certificate of mailing.			Jane Masse	y Licat	<u></u>
			(Typed or Printed Name of Per	rson Sign	ning Certificate)
		. 	Sculot Signatu	re)	
		•		,	
	·				
		Note: Cook an au monat h	are its over as different of molling		
		ivote: Lach paper must u	TAG ITS DAM CELIMICATE OF BEHING.		
	·				
		•			

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent			Docket No. ISPH-0625
In Re Application Of: B	rett P. Monia		·
Serial No.	Filing Date	Examiner	Group Art Unit
10/057,550	January 25, 2002	James Schultz	1635
Invention: ANTISENSI	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXPRI	ESSION
Owner of Record: Isis l	Pharmaceuticals, Inc.	·	
	TO THE COMMISS	ONER FOR PATENTS:	
the expiration date of the disclalmer, of prior Patent I be enforceable only for an patent granted on the insta In making the ab application that would exte patent, as presently shorte held unenforceable, is four under 37 C.F.R. 1.321, has the expiration of its full state. Check either box 1. For submissions	d during such period that it and the nt application and is binding upon the over disclaimer, the owner does not to the expiration date of the full sined by any terminal disclaimer, in the invalid by a court of competent just all claims cancelled by a reexaminatory term as presently shortened by a real or 2 below, if appropriate.	.S.C. 154 to 156 and 173, as preeby agrees that any patent so grante prior patent are commonly owner grantee, its successors and/or as of disclaim the terminal part of a statutory term as defined in 35 U.S. the event that it later expires for faurisdiction, is statutorily disclaimed nation certificate, is reissued, or is y any terminal disclaimer.	esently shortened by any terminal sted on the instant application shall ad. This agreement runs with any ssigns. ny patent granted on the instant C. 154 to 156 and 173 of the prior allure to pay a maintenance fee, is in whole or terminally disclaimed in any manner terminated prior to
undersigned is empowered I hereby declare information and belief are statements and the like so States Code and that such	to act on behalf of the organization that all statements made herein believed to be true; and further the made are punishable by fine or i willful false statements may jeopards an attorney of record.	. of my own knowledge are true a at these statements were made w mprisonment, or both, under Sect	and that all statements made on ith the knowledge that wiltful false ion 1001 of Title 18 of the United
Typed Terminal disclaim PTO suggested w	Signature Massey Licata For Printed Name er fee under 37 C.F.R. 1.20(d) included ording for terminal disclaimer was used as 7 C.F.R. 3.73(b) is required if terminal disclaimer.	nchanged.	signee.

→ PTOBF

CERTIFICATE OF	TRANSMISSION BY FAC	CSIMILE (37 CFR 1.8)	Docket No. ISPH-0625		
Applicant(s): Brett P. Monia					
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635		
Invention: ANTISENSE	OLIGONUCLEOTIDE MODI	JLATION BY RAF GENE E	KPRESSION		
-					
					
	•				
I hereby certify that this		Terminal Disclaimer (Identify type of correspondence)			
is being facsimile transn	nitted to the United States Pate		k. No. 703-872-9306)		
	·	•			
On February 2					
(Date)					
	· —•	Jane Mas	sey Licata		
		(1ypsa or Fruitea Name of I	wave segming cerupoutly		
		Jenaossy) seri (Signa	(ture)		
·		C (Signa	····················		
	•				
l					
	Note, E-b source	have ite our continues of mail-	y .		
	Note: Each paper must	have its own certificate of mailing	g.		
	Note: Each paper must				
	Note: Each paper must		g.		
	Note: Each paper must				
·					
·					
·					
·					

Termin Patent	Docket No. ISPH-0625			
In Re Application Of: B	rett P. Monia			
Serial No.	Filing Date	Examiner	Group Art Unit	
10/057,550	Јапиагу 25, 2002	James Schultz	1635	
Invention: ANTISENSI	E OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EX	PRESSION	
Owner of Record: Isis I	`harmaceuticals, Inc.			
	TO THE COMMISS	ONER FOR PATENTS:		
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,358,932. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1.				
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney of record.				
	Signature	Dated: February 27, 200)4	
	Massey Licata			
Terminal disclaime PTO suggested wo	or Printed Name or fee under 37 C.F.R. 1.20(d) included fee under 37 C.F.R. 1.20(d) included feeling for terminal disclaimer was under 37 C.F.R. 3.73(b) is required if terminal disclaimer.	nchanged.	assignee,	

ODDITION AND AR	TRANSMISSION BY FACS	SIMILE (37 CFR 1.8)	Docket No.		
Applicant(s): Brett P. M			ISPH-0625		
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635		
Invention: ANTISENSE	Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION				
	- -				
I hereby certify that this	·	Terminal Disclaimer			
		(Identify type of correspondence)			
	nitted to the United States Patent	t and Trademark Office (Fax. l	No. 703-87 2- 9306)		
on February 2					
(Date)					
			•		
·		Jane Masse; (Typed or Printed Nume of Per	y Licata son Signing Certificate)		
		TATHON OF FINER TABLE OF PER	g garayanay		
		Ja aansi eeti (Sighatur	<u></u>		
		• •			
	Note: Each paper must h	ave its own certificate of mailing.			
			•		
			•		

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent Docket No. ISPH-0625				
In Re Application Of: Brett P. Monia				
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635	
Invention: ANTISENSE	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXPRESS	ION	
Owner of Record: Isis P	harmaceuticals, Inc.			
	TO THE COMMISS	IONER FOR <u>PATENTS:</u>		
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,919,773. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. Pror submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willfulf false statements and the like so made are punishable by fine or imprisonment, or both, und				
JCHAMALCI	Signature Massey Licatu	Dated: February 27, 2004		
Terminal disclaims	or Printed Name er fee under 37 C.F.R. 1.20(d) inclu ording for terminal disclaimer was u	ded. Inchanged. minal disclaimer is signed by the assign	neė.	

			Docket No.			
CERTIFICATE OF	TRANSMISSION BY FAC	SIMILE (37 CFR 1.8)				
Applicant(s): Brett P. M	onia		ISPH-0625			
		Examiner	Group Art Unit			
Serial No.	Filing Date		1635			
10/057,550	January 25, 2002	James Schultz	1000			
Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION						
Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION						
			· · · · · · · · · · · · · · · · · · ·			
			-			
I hereby certify that this		Terminal Disclaimer				
· ·		(Identify type of correspondence)				
is being facsimile transm	nitted to the United States Paten	t and Trademark Office (Fax. I	No. 703-872-9306)			
Fab	17 2004					
on February 2						
(Dute)	,					
		Jane Masse	y Licata			
·	<u></u>	(Typed or Printed Name of Per	son Signing Certificate)			
		On any to				
	· · ·	Signatu.				
į						
	Note: Each paper must b	nave its own certificate of mailing.				
·						
	•		•			
1						
I						

1	al Disclaimer To Obviate A ing Rejection Over A Prior	1 4 1	Docket No. ISPH-0625	
In Re Application Of: Bi	rett P. Monia			
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635	
Invention: ANTISENSE	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXPRE	ESSION	
Owner of Record: Isis P	harmaceuticals, Inc.			
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,744,362. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutority disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. Por submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true: and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under				
Jane I Typed o Terminal disclaime PTO suggested wo	Signature Massey Licata or Printed Name rifee under 37 C.F.R. 1.20(d) includer rifeng for terminal disclaimer was under 37 C.F.R. 3.73(b) is required if term		ignee.	